Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711022 | 0.79 | KDM5B (0.46) | GSK3B | |
| SCHEMBL173216 | 0.76 | GSK3B (0.61) | GSK3BCYP2D6 | |
| SCHEMBL9906429 | 0.74 | GSK3B (0.60) | GSK3BCYP2D6 | |
| SCHEMBL137966 | 0.74 | GSK3B (0.60) | GSK3BCYP2D6 | |
| SCHEMBL9944038 | 0.74 | GSK3B (0.60) | GSK3BCYP2D6 | |
| SCHEMBL101767 | 0.74 | GSK3B (0.60) | GSK3BCYP2D6 | |
| SCHEMBL3139329 | 0.72 | GSK3B (0.57) | GSK3BCYP2D6 | |
| SCHEMBL12207252 | 0.72 | GSK3B (0.57) | GSK3BCYP2D6 | |
| SCHEMBL30595872 | 0.72 | HSP90AA1 (0.52) | GSK3BCYP2D6 | |
| SCHEMBL2814353 | 0.72 | HSP90AA1 (0.52) | GSK3BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001863-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-12-17 | — | — | EP | claimed |
| WO-2007119463-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-25 | — | — | WO | claimed |
| US-11878018-B1 | Phosphorylation of Syntaxin 17 by TBK1 controls autophagy initiation | UNM RAINFOREST INNOVATIONS (US) | 2024-01-23 | — | — | US | disclosed |
| EP-2001863-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007119463-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878018-B1 | Phosphorylation of Syntaxin 17 by TBK1 controls autophagy initiation | STXBP1, TBK1, STX18 | GSK3B 152/4885CYP2D6 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.